دورية أكاديمية
Recent advances in amphotericin B delivery strategies for the treatment of leishmaniases.
| العنوان: | Recent advances in amphotericin B delivery strategies for the treatment of leishmaniases. |
|---|---|
| المؤلفون: | Lanza JS; Faculty of Pharmacy, Antiparasite Chemotherapy, UMR 8076 CNRS BioCIS, University Paris-Saclay , Chatenay-Malabry , France., Pomel S; Faculty of Pharmacy, Antiparasite Chemotherapy, UMR 8076 CNRS BioCIS, University Paris-Saclay , Chatenay-Malabry , France., Loiseau PM; Faculty of Pharmacy, Antiparasite Chemotherapy, UMR 8076 CNRS BioCIS, University Paris-Saclay , Chatenay-Malabry , France., Frézard F; Department of Physiology and Biophysics, Institute of Biological Sciences, Universidade Federal de Minas Gerais (UFMG) , Belo Horizonte , Brazil. |
| المصدر: | Expert opinion on drug delivery [Expert Opin Drug Deliv] 2019 Oct; Vol. 16 (10), pp. 1063-1079. Date of Electronic Publication: 2019 Aug 30. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Informa Healthcare Country of Publication: England NLM ID: 101228421 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-7593 (Electronic) Linking ISSN: 17425247 NLM ISO Abbreviation: Expert Opin Drug Deliv Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: London : Informa Healthcare Original Publication: London : Ashley Publications, Ltd. |
| مواضيع طبية MeSH: | Amphotericin B/*administration & dosage , Antiprotozoal Agents/*administration & dosage , Leishmaniasis/*drug therapy, Animals ; Drug Delivery Systems ; Humans |
| مستخلص: | Introduction : Among the drugs in clinical use for the treatment of leishmaniases, amphotericin B (AmB) is the most effective and has been the most extensively studied for the development of drug delivery strategies. Liposomal amphotericin B (AmBisome®) still represents the best therapeutic option for leishmaniases, however, its clinical efficacy depends on the patient immunological status and the endemic region. Moreover, the need for parenteral administration, its side effects and high cost significantly limit its use in developing countries. Areas covered : This article provides insight into the novel drug delivery strategies that were investigated for AmB over the last 5 years and a final critical selection of emerging concepts and most promising approaches, based on the significance of preclinical antileishmanial and toxicity data. Expert opinion : The feasibility of oral and topical delivery of AmB has been established in experimental models of leishmaniases. Highly effective AmB nanocarriers containing active targeting ligand and/or immunomodulatory component have also emerged. Translating these advances to the clinic still relies on the full demonstration of safety and efficacy in humans and on the viability and cost-effectiveness of large-scale industrial production. |
| فهرسة مساهمة: | Keywords: AmBisome; amphotericin B; chemotherapy; drug delivery; immunochemotherapy; leishmaniasis; nanocarrier |
| المشرفين على المادة: | 0 (Antiprotozoal Agents) 0 (liposomal amphotericin B) 7XU7A7DROE (Amphotericin B) |
| تواريخ الأحداث: | Date Created: 20190822 Date Completed: 20200310 Latest Revision: 20200310 |
| رمز التحديث: | 20240628 |
| DOI: | 10.1080/17425247.2019.1659243 |
| PMID: | 31433678 |
| قاعدة البيانات: | MEDLINE |
PDF full text from Publisher | تدمد: | 1744-7593 |
|---|---|
| DOI: | 10.1080/17425247.2019.1659243 |